What is the recommended empiric antibiotic therapy for a patient presenting with a soft tissue infection?

Empiric Antibiotic Therapy for Soft Tissue Infections

First, classify the infection as purulent versus non-purulent, then assess severity—this determines your empiric antibiotic choice.

The IDSA recommends that all soft tissue infections be initially classified as purulent or non-purulent to guide appropriate empiric therapy 1, 2. This classification is the critical first step before selecting antibiotics.

---

Purulent Infections (Abscesses, Furuncles, Carbuncles)

Incision and drainage is the primary treatment; antibiotics are adjunctive for more severe infections 2.

Mild Purulent Infections

• If local MRSA prevalence is <10-15% and no MRSA risk factors: Cephalexin 500 mg PO QID or dicloxacillin 500 mg PO QID 2, 3
• If local MRSA prevalence >10-15% OR patient has MRSA risk factors (prior MRSA infection, recent hospitalization, recent antibiotics): Use anti-MRSA coverage 1, 2:
  • Trimethoprim-sulfamethoxazole 160-800 mg (double-strength) PO BID
  • Doxycycline 100 mg PO BID
  • Clindamycin 300-450 mg PO TID
  • Linezolid 600 mg PO BID 2, 4

Severe Purulent Infections (Systemic toxicity, extensive erythema >5 cm, fever)

• Vancomycin 15 mg/kg IV every 12 hours plus drainage 1
• Alternatives: Linezolid 600 mg IV/PO BID, daptomycin 4-6 mg/kg IV daily 1, 2

---

Non-Purulent Infections (Cellulitis, Erysipelas)

Mild to Moderate Non-Purulent Infections

First-line therapy targets streptococci and methicillin-susceptible S. aureus:

• Cephalexin 500 mg PO QID (preferred for convenience and tolerability) 2, 3
• Alternatives: Dicloxacillin 500 mg PO QID, clindamycin 300-450 mg PO TID 1, 2

Add MRSA coverage if local prevalence >10-15% or risk factors present:

• Add trimethoprim-sulfamethoxazole or doxycycline to beta-lactam, OR
• Use clindamycin monotherapy 1, 2

Severe Non-Purulent Infections (Systemic toxicity, hypotension, organ dysfunction)

Broad-spectrum IV therapy is mandatory:

• Vancomycin 15 mg/kg IV every 12 hours PLUS piperacillin-tazobactam 4.5 g IV every 6-8 hours 1, 2
• Alternative combinations:
  • Vancomycin PLUS ceftriaxone 1 g IV daily plus metronidazole 500 mg IV every 8 hours 1
  • Linezolid 600 mg IV BID PLUS piperacillin-tazobactam 1

---

Necrotizing Fasciitis or Gas Gangrene

Urgent surgical debridement is mandatory—antibiotics alone are insufficient 1, 5.

Empiric Therapy (Polymicrobial or Monomicrobial)

• Clindamycin 600-900 mg IV every 8 hours (for toxin suppression) PLUS piperacillin-tazobactam 4.5 g IV every 6-8 hours 1, 5
• Alternative: Clindamycin PLUS ceftriaxone 1 g IV daily plus metronidazole 500 mg IV every 8 hours 1
• Add vancomycin 15 mg/kg IV every 12 hours if MRSA or community-acquired MRSA suspected 1, 2

If Group A Streptococcus Confirmed

• Penicillin G 4 million units IV every 4 hours PLUS clindamycin 600-900 mg IV every 8 hours 1

---

Diabetic Foot Infections

Mild Infections (No systemic toxicity, <2 cm erythema)

Target aerobic gram-positive cocci only:

• Dicloxacillin 500 mg PO QID, cephalexin 500 mg PO QID, clindamycin 300-450 mg PO TID, or amoxicillin-clavulanate 875 mg PO BID 1, 2

Moderate to Severe Infections (Systemic toxicity, >2 cm erythema, deep tissue involvement)

Broad-spectrum coverage for gram-positives, gram-negatives, and anaerobes:

• Ampicillin-sulbactam 3 g IV every 6 hours 1
• Alternatives: Piperacillin-tazobactam 4.5 g IV every 6-8 hours, ertapenem 1 g IV daily, or ceftriaxone 1 g IV daily plus metronidazole 500 mg IV every 8 hours 1, 2
• Add vancomycin 15 mg/kg IV every 12 hours if high local MRSA prevalence or prior MRSA history 1, 2

Avoid empiric Pseudomonas coverage unless patient has risk factors (recent hospitalization, recent broad-spectrum antibiotics, chronic wounds) 1.

---

Surgical Site Infections

Trunk or Extremity (Away from Axilla/Perineum)

• Cephalexin 500 mg PO every 6 hours or cefazolin 1 g IV every 8 hours 1
• Add vancomycin if MRSA risk factors present 1

Axilla or Perineum (Anaerobic Coverage Required)

• Metronidazole 500 mg IV every 8 hours PLUS ciprofloxacin 400 mg IV every 12 hours OR ceftriaxone 1 g IV daily 1

Intestinal or Genitourinary Tract Surgery

• Piperacillin-tazobactam 4.5 g IV every 6-8 hours 1
• Alternatives: Ertapenem 1 g IV daily, or ceftriaxone 1 g IV daily plus metronidazole 500 mg IV every 8 hours 1

---

Duration of Therapy

• Uncomplicated SSTIs: 5-7 days (if clinical improvement by day 5, no need to extend to 10 days) 2, 3
• Complicated SSTIs: 7-14 days depending on severity and clinical response 2, 6
• Diabetic foot infections: 1-2 weeks for mild, 2-3 weeks for moderate to severe 1
• Treat until resolution of infection signs, NOT until complete wound healing 1, 6

---

Transition to Oral Therapy

Switch to oral antibiotics when patient is afebrile, WBC normalizing, and erythema/swelling improving 6.

Recommended Oral Regimens

• For polymicrobial or anaerobic coverage: Amoxicillin-clavulanate 875 mg PO BID 6
• For MRSA coverage: Continue trimethoprim-sulfamethoxazole 160-800 mg PO BID or linezolid 600 mg PO BID until cultures exclude MRSA 6
• For simple cellulitis: Cephalexin 500 mg PO QID 3, 6

---

Critical Pitfalls to Avoid

• Do NOT use cephalexin or other beta-lactams if MRSA is suspected or confirmed—they have zero activity against MRSA 3
• Do NOT use cephalexin for necrotizing infections, animal/human bites, or infections near the rectum/genitals—these require anaerobic coverage 3
• Do NOT delay surgical debridement for necrotizing fasciitis—antibiotics alone are fatal 1, 5
• Do NOT add empiric Pseudomonas coverage for diabetic foot infections unless specific risk factors present (recent hospitalization, chronic wounds, prior Pseudomonas isolation) 1
• Do NOT continue antibiotics until complete wound healing—stop when infection signs resolve 1, 6
• Do NOT discontinue MRSA coverage prematurely if started empirically—wait for culture results 6